Influence of ketanserin on the effects of methylenedioxymethamphetamine on body temperature in the mouse
J. R. Docherty, S. Bexis
Autonomic and Autacoid Pharmacology October 1, 2013 DOI: 10.1111/aap.12009 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Controlled experimental animal study Peer reviewed |
|---|---|
| Population | Conscious mice with implanted intra-abdominal temperature probes; rat aorta and rat vas deferens tissue in vitro |
| Interventions | MDMA Ketanserin Prazosin |
| Dose | MDMA 20 mg/kg; ketanserin 0.5 mg/kg; prazosin 0.1 mg/kg |
| Duration | Temperature monitored for at least 150 minutes after MDMA injection; mice allowed 2 weeks recovery after probe implantation |
| Topics | MDMA |
| Key findings | MDMA (20 mg/kg) produced a slowly developing hyperthermia in mice, reaching a maximum rise of 1.24 °C at 150 minutes. Ketanserin (0.5 mg/kg) instead revealed marked early hypothermia to MDMA, mimicked by the α1-adrenoceptor antagonist prazosin (0.1 mg/kg). The authors conclude ketanserin modulates MDMA hyperthermia in a manner consistent with α1-adrenoceptor antagonism and report no clear evidence that 5HT2 receptors mediate the hyperthermic response. |
Abstract
Summary: We have investigated the ability of the 5HT2‐receptor antagonist ketanserin to affect the hyperthermia produced by methylenedioxymethamphetamine (MDMA) in conscious mice and examined whether α1‐adrenoceptor antagonist actions are involved. Mice were implanted with intra‐abdominal temperature probes under anaesthesia and allowed 2 weeks recovery. MDMA (20 mg kg−1) was administered subcutaneously 30 min after vehicle or test antagonist and effects on body temperature monitored by telemetry. Following vehicle, MDMA produced a slowly developing hyperthermia, reaching a maximum increase of 1.24 °C at 150 min postinjection. Ketanserin (0.5 mg kg−1) revealed a significant and marked early hypothermia to MDMA, an effect that is mimicked by the α1‐adrenoceptor antagonist prazosin (0.1 mg kg−1). Functional studies revealed antagonist actions of ketanserin at α1‐adrenoceptors in rat aorta and rat vas deferens in vitro indicative of α1‐adrenoceptor antagonist actions at the concentration used in vivo. In conclusion, ketanserin (0.5 mg kg−1) modulates the hyperthermic actions of MDMA in mice. Although we cannot rule out additional actions at 5HT2‐receptors, the actions of ketanserin are consistent with α1‐adrenoceptor antagonism. There is no clear evidence from this study that 5HT2‐receptors mediate the hyperthermic response to MDMA.
Comparable studies
Other preclinical and animal studies on MDMA, most cited first.
Citations in the library
Cites 11
- Small Changes in Ambient Temperature Cause Large Changes in 3,4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonin Neurotoxicity and Core Body Temperature in the Rat Journal of Neuroscience July 1, 1998
- The pharmacology of the acute hyperthermic response that follows administration of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats British Journal of Pharmacology 2002
- Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors Brain Research October 1, 1990
- The role of monoamines in the changes in body temperature induced by 3,4‐methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives British Journal of Pharmacology March 3, 2010
- Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in an animal model* Critical Care Medicine June 1, 2005
and 6 more in the library